The two-dose Pfizer-BioNTech Covid-19 vaccine provides adolescents with effective protection, a large Israeli study has found.
The analysis was based on data from nearly 200 000 adolescents (94 354 vaccinated and 94 354 unvaccinated) aged 12 to 18.
It showed that fully vaccinated participants were 93% less likely than their unvaccinated peers to contract symptomatic (displaying symptoms) infection with the Delta variant in the first few weeks after receiving their second dose.